Drug Trial Radar · NCT07752121
First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
190
Planned (sponsor's estimate)
Start
Sep 3, 2026
Primary completion
Aug 31, 2030
Study completion Aug 31, 2030
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Aug 7, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will observe adults with lower-risk myelodysplastic neoplasms (MDS) who have anemia requiring regular red blood cell transfusions and who are prescribed first-line luspatercept as part of routine medical care. The study will follow participants for up to 2 years to understand how often treatment leads to periods without transfusions, changes in hemoglobin levels, health-related quality of life, and safety outcomes. Information on treatment use and outcomes in routine clinical practice in Germany will also be collected.
Conditions
- Myelodysplastic Neoplasms
Interventions
LuspaterceptDrug
As per product label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants achieving red blood cell transfusion independence (RBC-TI) for at least 8 consecutive weeksTime frame: Up to Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Universitätsmedizin Johannes Gutenberg Universität Mainz
Mainz, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.